A case report of severe adverse reaction of exenatide: Anaphylactic shock.
Medicine (Baltimore) · 2022
Last updated 2026-05-28A 47-year-old man experienced anaphylactic shock after reusing exenatide, a diabetes medication. Symptoms included confusion, dizziness, nausea, vomiting, and a blood pressure drop to 85/50 mm Hg. He was treated with emergency medications and recovered after exenatide was stopped.
AI summary of the abstract below.
| Journal | Medicine (Baltimore), 2022 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.13 |
| NIH percentile | 9 |
| Molecules | exenatide |
Abstract
BACKGROUND: Anaphylactic shock is the severe state of the allergic reaction, which is rapid in onset and fatal. This is the first study that discusses the anaphylactic shock of exenatide reexposure in the patient who has interrupted exenatide treatment.
PATIENT CONCERNS: A 47-year-old man was treated with exenatide owing to high blood glucose and obesity. Then he developed localized urticarial on the face, white lip, hands tremble, nausea, vomit, chest stuffiness, dizziness, accompanying with confusion and dyspnea. His blood glucose was 4.6 millimole per liter (mmol/L) and blood pressure was 85/50 millimeters of mercury (mm Hg).
DIAGNOSIS: Exenatide-induced anaphylactic shock was considered.
INTERVENTIONS: The emergency electrocardiogram was performed. The patient was treated with dexamethasone sodium phosphate and calcium gluconate, combined with exenatide withdrawal. He also received oral antiallergic agents and intravenous nutrition treatment.
OUTCOMES: After antishock treatment, the clinical response gradually alleviated.
LESSONS: Although exenatide is not prone to anaphylaxis, it is the synthetic peptide that can induce antibody formation. Exenatide has immunogenicity with the potential to elicit an allergic reaction upon administration. Clinicians should always pay more attention to the anaphylactic shock of exenatide, when prescribing for diabetics.
Verbatim abstract via PubMed 36181058 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.